A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2002
10/16/2002	EP0637976B2 Medicament for disinfection of the oral cavity
10/16/2002	CN1374969A FAP-activated anti-tumor compounds
10/16/2002	CN1374968A 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, method fo r producing the same, medicaments containing these compounds and their use
10/16/2002	CN1374967A Compounds for the treatment of ischemia
10/16/2002	CN1374955A Oxa-and thiazole derivatives useful as antidiabetic and antibesity agents
10/16/2002	CN1374873A Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions
10/16/2002	CN1374865A Nociceptin receptor ORL-1 agonists for use in treating cough
10/16/2002	CN1374861A Methods for modulating the human sexual response
10/16/2002	CN1374857A Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
10/16/2002	CN1374838A Method for stabilizing liquid nutritional products and products so stabilized
10/16/2002	CN1092652C 2-imidazolinylaminoindole compound and composition containing the same use
10/16/2002	CN1092642C Quinoline derivatives as tachykinin NK 3 receptor antagonists
10/15/2002	US6465621 Polypeptides and polynucleotides of the gtp-binding protein family
10/15/2002	US6465526 Natural mixture composed of higher primary aliphatic alcohols obtained from bee wax for the treatment of gastric and duodenal ulcers that also present antiinflamatory activity
10/15/2002	US6465518 2-amino-5-fluoro-6-(1-iminoethylamino)-hept-4-enoic acid, for example; treating or preventing various causes of inflammation
10/15/2002	US6465517 Taurine, coenzyme q10 and additionally creatine, l-carnitine, certain vitamins and minerals, carbohydrates, proteins, fats and herbal extracts
10/15/2002	US6465516 Increasing nitric oxide production by administering inhibitors of hmg-coa-reductase; treatment of diseases related to endothelial dysfunction
10/15/2002	US6465514 Methods and compositions for the promotion of hair growth
10/15/2002	US6465487 Inhibition of membrane-associated viral replication
10/15/2002	US6465458 Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
10/15/2002	US6465449 Heteroaromatic bicyclic derivatives useful as anticancer agents
10/15/2002	US6465445 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
10/15/2002	US6465444 Protein tyrosine phosphatases(ptp-1b); antidiabetic, antitumor and anorexigenic agents; combination therapy
10/15/2002	US6465441 Screening method for modulation of human mast cell activation
10/15/2002	US6465440 Antimutagenic compositions for treatment and prevention of photodamage to skin
10/15/2002	US6465436 Method for treating alcohol intoxication and alcohol abuse
10/15/2002	US6465421 Promoting the growth of body and/or head hair and/or combatting the loss of such hair via cyclooxygenase treatment, as well as, contrariwise, retarding and/or preventing the growth of body/cranial hair via lipoxygenase treatment
10/15/2002	US6465192 Compounds and methods for the inhibition of protein-protein interactions
10/15/2002	US6465187 Inhibition of gene expression of antiapoptotic genes to treat mast cell mediated inflammatory disorders
10/15/2002	US6465021 Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
10/15/2002	US6465011 Formulations comprising lipid-regulating agents
10/15/2002	US6465008 For therapy of tumors
10/15/2002	US6464994 Diaper dermatitis preventative medication and a method for making and using same
10/15/2002	US6464987 Pharmaceutical compositions capable of being gelled
10/15/2002	US6464986 Method for treating pain by peripheral administration of a neurotoxin
10/15/2002	US6464981 Therapeutic agent for a cancer and method of screening the same, and health-care auxiliary food
10/15/2002	US6464959 Protective colloid stabilizer.
10/15/2002	CA2337750C Therapeutic or cosmetic compositions containing dimeric or polymeric forms of hydroxyacids, and their therapeutic use
10/15/2002	CA2191837C Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
10/10/2002	WO2002079785A2 Phosphoprotein target for insulin and its antagonists
10/10/2002	WO2002079748A2 Withasol and methods of use
10/10/2002	WO2002079517A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
10/10/2002	WO2002079499A1 Pd-1, a receptor for b7-4, and uses therefor
10/10/2002	WO2002079458A1 Central nerve system precursor cells inducing synaptogenic neurons in spinal cord
10/10/2002	WO2002079448A2 G-protein coupled receptors
10/10/2002	WO2002079441A2 Secreted proteins
10/10/2002	WO2002079415A2 Reducing the immunogenicity of fusion proteins
10/10/2002	WO2002079408A2 Short bioactive peptides and methods for their use
10/10/2002	WO2002079404A2 Cytoskeleton-associated proteins
10/10/2002	WO2002079255A1 RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
10/10/2002	WO2002079238A2 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis
10/10/2002	WO2002079232A2 Reducing the immunogenicity of fusion proteins
10/10/2002	WO2002079197A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/10/2002	WO2002079192A1 Novel tyrosine kinase inhibitors
10/10/2002	WO2002079169A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002	WO2002079157A1 Aryl oxime-piperazines useful as ccr5 antagonists
10/10/2002	WO2002079152A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
10/10/2002	WO2002079143A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
10/10/2002	WO2002078863A1 Generation of pharmaceutical agent particles using focused acoustic energy
10/10/2002	WO2002078766A2 Combination therapy
10/10/2002	WO2002078745A2 Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
10/10/2002	WO2002078736A2 Antiallergic pharmaceutical composition
10/10/2002	WO2002078731A1 Module of pd-1 interactions with its ligands
10/10/2002	WO2002078730A2 Use of neublastin polypeptides for treating neuropathic pain
10/10/2002	WO2002078720A2 Antibiotics from bacteria isolated from amphibian skin
10/10/2002	WO2002078719A1 Antitumor methods and compositions comprising sesquiterpene derivatives
10/10/2002	WO2002078716A2 Methylated promoters for intraductal treatment of breast cancer
10/10/2002	WO2002078706A1 Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the inhibition for the treatment of cancer
10/10/2002	WO2002078691A1 Duloxetine for treatment of hot flashes
10/10/2002	WO2002078684A2 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
10/10/2002	WO2002078683A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
10/10/2002	WO2002078678A2 Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
10/10/2002	WO2002078648A2 Topical composition comprising an antifungal
10/10/2002	WO2002078643A2 Immunomodulation and effect on cell processes relating to serotonin family receptors
10/10/2002	WO2002078639A2 A method of treating proliferative diseases using eg5 inhibitors
10/10/2002	WO2002078638A2 Morpholino imaging and therapy
10/10/2002	WO2002078633A2 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
10/10/2002	WO2002078629A2 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
10/10/2002	WO2002078626A2 Therapeutic combinations for cardiovascular and inflammatory indications
10/10/2002	WO2002078625A2 Therapeutic combinations for cardiovascular and inflammatory indications
10/10/2002	WO2002078620A2 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
10/10/2002	WO2002078598A2 Peptides and antibodies to muc 1 proteins
10/10/2002	WO2002078580A1 Condom with an erectogenic composition
10/10/2002	WO2002078523A2 Agent for the treatment of overactive bladder
10/10/2002	WO2002078458A1 Mixtures of fructose and lactose as a low-calorie bulk sweetener with reduced glycemic index
10/10/2002	WO2002078444A1 Anticancer and chemopreventative agents and methods of use thereof
10/10/2002	WO2002062212A3 A personal condition management system
10/10/2002	WO2002060422A3 Treatment of diabetes mellitus using vardenafil
10/10/2002	WO2002060386A3 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)
10/10/2002	WO2002057287A3 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
10/10/2002	WO2002041827A3 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
10/10/2002	WO2002026820A3 Immunomodulatory protein derived from the yaba monkey tumor virus
10/10/2002	WO2002010766A3 Assay method, peptides and reagent kits for testing mrp-specific inhibitors
10/10/2002	WO2002004612A3 Drug metabolizing enzymes
10/10/2002	WO2001098353A3 Secreted proteins
10/10/2002	WO2001095895A3 Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
10/10/2002	WO2001093852A3 Method of treating pain using nalbuphine and opioid antagonists
10/10/2002	WO2001093845A3 Carboxyalkylether-acat inhibitor combinations
10/10/2002	WO2001077174A3 Human transporters and ion channels
10/10/2002	WO2001074382A9 Method of treatment using ligand-immunogen conjugates

1 ... 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 ... 1151